Showing 9 of 0 results

• Using large language models to extract PD-L1 testing details from electronic health records

  Poster presented at: ISPOR US 2024; May 5-8, 2024; Atlanta, GA

  • Real-world evidence
  • Publication summary
  • Publications
  • Machine learning
• Assessing the potential value of the Flatiron Health commercial mortality data combined with publicly available death data for non-oncology research

  Poster presented at: ISPOR US 2024; May 5-8, 2024; Atlanta, GA

  • Real-world evidence
  • Publication summary
  • Publications
• Performance assessment of a disease-agnostic treatment sequencing heuristic for deriving line of therapy in a real-world, rare, multi-tumor cohort across tumor mutational burden status

  Poster presented at: ISPOR US 2024; May 5-8, 2024; Atlanta, GA

  • Real-world evidence
  • Publication summary
  • Publications
  • Methodology
• Oncology practice setting classification in the US: Considerations for real world evidence

  Poster presented at: ISPOR US 2024; May 5-8, 2024; Atlanta, GA

  • Real-world evidence
  • Publication summary
  • Publications
• FDA and Flatiron Health join forces to evaluate real-world outcomes in patients with organ impairment
  • Real-world evidence
  • Article
  • Regulatory
• Advancing equity in cancer care: Unveiling insights from the 2023 Real-World Data Impact Award
  • Real-world evidence
  • Video
  • Health equity
• Navigating Medicare drug price negotiation in oncology: The need for real-world evidence
  • Real-world evidence
  • Article
  • Regulatory
• Transporting comparative effectiveness evidence between countries: considerations for health technology assessment

  Pharmacoeconomics

  • Real-world evidence
  • Video
  • Publication summary
  • Publications
  • HTA and market access
• Real-world clinical efficacy of epidermal growth factor receptor inhibitors in patients with early-onset, metastatic colorectal cancer

  ASCO GI

  • Real-world evidence
  • Publication summary
  • Publications
  • Colorectal cancer